Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Chiramel J, Backen AC, Pihlak R, Lamarca A, Frizziero M, Tariq NU, Hubner RA, Valle JW, Amir E, McNamara MG.

Int J Mol Sci. 2017 Apr 26;18(5). pii: E909. doi: 10.3390/ijms18050909. Review.

2.

Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer.

Ricciardi S, Tomao S, de Marinis F.

Lung Cancer (Auckl). 2010 Dec 20;2:1-9. doi: 10.2147/LCTT.S10167. eCollection 2011. Review.

3.

Cutaneous complications of molecular targeted therapy used in oncology.

Lupu I, Voiculescu N, Bacalbasa N, Cojocaru I, Vrancian V, Giurcaneanu C.

J Med Life. 2016 Jan-Mar;9(1):19-25. Review.

4.

Mechanisms underlying skin disorders induced by EGFR inhibitors.

Holcmann M, Sibilia M.

Mol Cell Oncol. 2015 Jun 1;2(4):e1004969. doi: 10.1080/23723556.2015.1004969. eCollection 2015 Oct-Dec. Review.

5.

Concomitant cetuximab and radiation therapy: A possible promising strategy for locally advanced inoperable non-melanoma skin carcinomas.

Della Vittoria Scarpati G, Perri F, Pisconti S, Costa G, Ricciardiello F, Del Prete S, Napolitano A, Carraturo M, Mazzone S, Addeo R.

Mol Clin Oncol. 2016 Apr;4(4):467-471. Epub 2016 Jan 27.

6.

Skin problems and EGFR-tyrosine kinase inhibitor.

Kozuki T.

Jpn J Clin Oncol. 2016 Apr;46(4):291-8. doi: 10.1093/jjco/hyv207. Epub 2016 Jan 29. Review.

7.

Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitors.

Lupu I, Voiculescu VM, Bacalbasa N, Prie BE, Cojocaru I, Giurcaneanu C.

J Med Life. 2015;8 Spec Issue:57-61. Review.

8.

Dermatological Side Effects of Epidermal Growth Factor Receptor Inhibitors: 'PRIDE' Complex.

Madke B, Gole P, Kumar P, Khopkar U.

Indian J Dermatol. 2014 May;59(3):271-4. doi: 10.4103/0019-5154.131398.

9.

Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective.

Wehler TC, Graf C, Möhler M, Herzog J, Berger MR, Gockel I, Lang H, Theobald M, Galle PR, Schimanski CC.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1667-72. doi: 10.1007/s00432-013-1483-4. Epub 2013 Aug 7. Erratum in: J Cancer Res Clin Oncol. 2013 Nov;139(11):1961-2.

10.

Erlotinib induced trichomegaly of the eyelashes.

Jeon SH, Ryu JS, Choi GS, Kim JS, Kwon HY, Kim MS, Nam HS, Cho JH, Kwak SM, Lee HL, Kim HJ, Hong GJ.

Tuberc Respir Dis (Seoul). 2013 Jan;74(1):37-40. doi: 10.4046/trd.2013.74.1.37. Epub 2013 Jan 31.

11.

Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor.

Bangsgaard N, Houtkamp M, Schuurhuis DH, Parren PW, Baadsgaard O, Niessen HW, Skov L.

PLoS One. 2012;7(6):e39706. doi: 10.1371/journal.pone.0039706. Epub 2012 Jun 25.

12.

Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.

Bachet JB, Peuvrel L, Bachmeyer C, Reguiai Z, Gourraud PA, Bouché O, Ychou M, Bensadoun RJ, Dreno B, André T.

Oncologist. 2012;17(4):555-68. doi: 10.1634/theoncologist.2011-0365. Epub 2012 Mar 16. Review.

13.

Gefitinib-induced hair alterations.

Zheng S, Pan YL, Wang JL, Huang KE, Liu JH, Wang J, Chen XQ.

BMJ Case Rep. 2009;2009. pii: bcr09.2008.0878. doi: 10.1136/bcr.09.2008.0878. Epub 2009 Mar 17.

14.

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA; MASCC Skin Toxicity Study Group.

Support Care Cancer. 2011 Aug;19(8):1079-95. doi: 10.1007/s00520-011-1197-6. Epub 2011 Jun 1. Review.

15.

Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.

Pinto C, Barone CA, Girolomoni G, Russi EG, Merlano MC, Ferrari D, Maiello E; American Society of Clinical Oncology; European Society of Medical Oncology.

Oncologist. 2011;16(2):228-38. doi: 10.1634/theoncologist.2010-0298. Epub 2011 Jan 27.

16.
17.

Lack of Cetuximab induced skin toxicity in a previously irradiated field: case report and review of the literature.

Kanakamedala MR, Packianathan S, Vijayakumar S.

Radiat Oncol. 2010 May 17;5:38. doi: 10.1186/1748-717X-5-38.

18.

Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.

Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M, Colucci G, Del Prete S, Tonini G.

Oncologist. 2010;15(1):85-92. doi: 10.1634/theoncologist.2009-0143. Epub 2010 Jan 5.

19.

Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies.

Giovannini M, Gregorc V, Belli C, Roca E, Lazzari C, Viganò MG, Serafico A, Villa E.

J Oncol. 2009;2009:849051. doi: 10.1155/2009/849051. Epub 2009 Jun 22.

20.

Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations.

Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M.

Curr Oncol. 2009 Jan;16(1):16-26.

Supplemental Content

Support Center